Browse studies

Find your next paid study

32 recruiting studies matching your filters

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart dise…

AtherosclerosisCardiovascular DiseasesLipoprotein(a)

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07613294

Observational

Magnetic Resonance of Body, Arterial Wall, and Angiography Imaging for Non- Invasive Assessment of Arterial Distensibility, Endothelial Dysfunction and Atherosclerotic Disease Using 1.5T and High Field (3T) MRI: A Technical Development Study of Cardiac and Body Imaging

Background: \- Imaging tests, such as magnetic resonance imaging (MRI), can provide information about heart and blood vessels. The tests let doctors can see t…

HealthyObesityDiabetes+2 more

Estimated

~$10 – $5,625

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT01399385

Phase 2

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Clazakizumab in Reducing hsCRP in Adults With Elevated hsCRP and Established ASCVD or at Increased Risk for ASCVD Events

The purpose of this study is to measure the change in high-sensitivity C-reactive protein (hsCRP), a marker of inflammation in the body, with clazakizumab comp…

AtherosclerosisCardiovascular DiseaseObesity+3 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07783802

Phase 3

Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if …

Coronary Artery Disease Risk Factors MultipleCoronary Artery Disease ProgressionPrevention & Control+1 more

Estimated

~$10 – $6,250

Duke UniversityNCT07232069

Phase 3

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk: A Randomized Trial

The Low dose ColchicinE in pAtients with peripheral Artery DiseasE to address residual vascular Risk (LEADER-PAD) trial will evaluate if anti-inflammatory ther…

Peripheral Arterial DiseaseAtherosclerosis of ExtremitiesInflammation

Estimated

~$10 – $7,500

Population Health Research InstituteNCT04774159

Cardiovascular Disease Discovery Protocol

Background: \- Researchers are interested in studying individuals who have known or suspected metabolic, inflammatory or genetic diseases that may put them at…

Metabolic DiseaseObesityLi-Fraumeni Syndrome+3 more

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT01143454

Disease Pathogenesis and Natural History of Lipid Disorders

This study will evaluate people with dyslipidemias - disorders that affect the fat content in the blood. Fats, or lipids, such as cholesterol and triglycerides…

HypercholesterolemiaAtherosclerosis

Estimated

~$10 – $675

National Heart, Lung, and Blood Institute (NHLBI)NCT00353782

Phase 2

A Phase IIa, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Selnoflast in Reducing Vascular Inflammation in Patients With Atherosclerosis at Risk for Major Adverse Cardiac Events

The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adve…

Atherosclerosis

Estimated

~$10 – $8,750

Genentech, Inc.NCT07448038

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of VERVE-102, a One-Time Dose Gene Editing Medicine, in Adults With or at High Risk for Atherosclerotic Cardiovascular Disease (ASCVD) Who Require Additional Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering

The purpose of this study is to measure the change in bad cholesterol (LDL-C) with VERVE-102 compared to placebo in adults who have plaque buildup in their art…

AtherosclerosisCardiovascular DiseaseHypercholesterolemia

Estimated

~$10 – $8,750

Verve Therapeutics, Inc.NCT07839936

Study of the Effect of Innate Immunity on the Inflammatory Response to Endotoxin

Background: \- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by cau…

AsthmaAtherosclerosisMetabolic Syndrome+2 more

Estimated

~$10 – $675

National Institute of Environmental Health Sciences (NIEHS)NCT01143480

Phase 2

A Randomized, Multicenter, Double-Blind, Parallel, Placebo-controlled Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of YN001 in Adults With Coronary Atherosclerosis

This study is designed to evaluate the efficacy and safety of intravenously administered YN001 in patients diagnosed with coronary atherosclerosis, who are rec…

AtherosclerosisCoronary Artery Disease

Estimated

~$10 – $8,750

Beijing Inno Medicine Co., Ltd.NCT07521007

Phase 2

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus

Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart…

Systemic Lupus ErythematosusCardiovascular DiseasePremature Atherosclerosis

Estimated

~$10 – $5,625

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT05440422